|
1
|
Wang T, Ma LM, Zhang HP, Wang HW, Yang LH
and Qiao ZH: The effect of arsenic trioxide
(As2O3) combined with BSO on K562/ADM cells
and its mechanisms. Zhonghua Xue Ye Xue Za Zhi. 28:438–443.
2007.(In Chinese).
|
|
2
|
Mathas S, Lietz A, Janz M, et al:
Inhibition of NF-κB essentially contributes to arsenic-induced
apoptosis. Blood. 102:1028–1034. 2003.
|
|
3
|
Thomas H and Coley HM: Overcoming
multidrug resistance in cancer: an update on the clinical strategy
of inhibiting p-glycoprotein. Cancer Control. 10:159–165.
2003.PubMed/NCBI
|
|
4
|
Lee HR, Cheong HJ, Kim SJ, Lee NS, Park HS
and Won JH: Sulindac enhances arsenic trioxide-mediated apoptosis
by inhibition of NF-κB in HCT116 colon cancer cells. Oncol Rep.
20:41–47. 2008.PubMed/NCBI
|
|
5
|
Mathieu J and Besancon F: Arsenic trioxide
represses NF-κB activation and increases apoptosis in ATRA-treated
APL cells. Ann NY Acad Sci. 1090:203–208. 2006.
|
|
6
|
Park MJ, Lee JY, Kwak HJ, et al: Arsenic
trioxide (As2O3) inhibits invasion of HT1080
human fibrosarcoma cells: role of nuclear factor-κB and reactive
oxygen species. J Cell Biochem. 95:955–969. 2005.PubMed/NCBI
|
|
7
|
Bentires-Alj M, Barbu V, Fillet M, et al:
NF-κB transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003.
|
|
8
|
Kuo MT, Liu Z, Wei Y, et al: Induction of
human MDR1 gene expression by 2-acetylaminofluorene is
mediated by effectors of the phosphoinositide 3-kinase pathway that
activate NF-κB signaling. Oncogene. 21:1945–1954. 2002.
|
|
9
|
Tanigawara Y: Role of P-glycoprotein in
drug disposition. Ther Drug Monit. 22:137–140. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Callen DF, Baker E, Simmers RN, Seshadri R
and Roninson IB: Localization of the human multiple drug resistance
gene, MDR1, to 7q21.1. Hum Genet. 77:142–144. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scotto KW and Johnson RA: Transcription of
the multidrug resistance gene MDR1: a therapeutic target. Mol
Interv. 1:117–125. 2001.PubMed/NCBI
|
|
12
|
Hirsch-Ernst KI, Ziemann C, Schmitz-Salue
C, Foth H and Kahl GF: Modulation of P-glycoprotein and
mdr1b mRNA expression by growth factors in primary rat
hepatocyte culture. Biochem Biophys Res Commun. 215:179–185.
1995.
|
|
13
|
Hirsch-Ernst KI, Ziemann C, Foth H, Kozian
D, Schmitz-Salue C and Kahl GF: Induction of mdr1b mRNA and
P-glycoprotein expression by tumor necrosis factor alpha in primary
rat hepatocyte cultures. J Cell Physiol. 176:506–515. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fardel O, Lecureur V, Daval S, Corlu A and
Guillouzo A: Up-regulation of P-glycoprotein expression in rat
liver cells by acute doxorubicin treatment. Eur J Biochem.
246:186–192. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng Q, Lee HH, Li Y, Parks TP and Cheng
G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of
chemoresistance, which can be overcome by NF-κB inhibition.
Oncogene. 19:4936–4940. 2000.PubMed/NCBI
|
|
16
|
Chin KV, Ueda K, Pastan I and Gottesman
MM: Modulation of activity of the promoter of the human MDR1 gene
by Ras and p53. Science. 255:459–462. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Synold TW, Dussault I and Forman BM: The
orphan nuclear receptor SXR coordinately regulates drug metabolism
and efflux. Nat Med. 7:584–590. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bush JA and Li G: Regulation of the
Mdr1 isoforms in a p53-deficient mouse model.
Carcinogenesis. 23:1603–1607. 2002.
|
|
19
|
Sen R and Baltimore D: Inducibility of κ
immunoglobulin enhancer-binding protein NF-κB by a
posttranslational mechanism. Cell. 47:921–928. 1986.
|
|
20
|
Lin L, DeMartino GN and Greene WC:
Cotranslational biogenesis of NF-κB p50 by the 26S proteasome.
Cell. 92:819–828. 1998.
|
|
21
|
Schmitz ML and Baeuerle PA: The p65
subunit is responsible for the strong transcription activating
potential of NF-kappa B. EMBO J. 10:3805–3817. 1991.PubMed/NCBI
|
|
22
|
Quivy V and Van Lint C: Regulation at
multiple levels of NF-κB-mediated transactivation by protein
acetylation. Biochem Pharmacol. 68:1221–1229. 2004.
|
|
23
|
Wu M, Lee H, Bellas RE, et al: Inhibition
of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J.
15:4682–4690. 1996.PubMed/NCBI
|
|
24
|
Ryan KM, Ernst MK, Rice NR and Vousden KH:
Role of NF-κB in p53-mediated programmed cell death. Nature.
404:892–897. 2000.
|
|
25
|
Pham LV, Tamayo AT, Yoshimura LC, et al: A
CD40 signalosome anchored in lipid rafts leads to constitutive
activation of NF-κB and autonomous cell growth in B cell lymphomas.
Immunity. 16:37–50. 2002.PubMed/NCBI
|
|
26
|
Ueda M, Kokura S, Imamoto E, et al:
Blocking of NF-κB activation enhances the tumor necrosis factor
α-induced apoptosis of a human gastric cancer cell line. Cancer
Lett. 193:177–182. 2003.
|
|
27
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-κB antiapoptosis: induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998.
|
|
28
|
Thevenod F, Friedmann JM, Katsen AD and
Hauser IA: Up-regulation of multidrug resistance P-glycoprotein via
nuclear factor-κB activation protects kidney proximal tubule cells
from cadmium- and reactive oxygen species-induced apoptosis. J Biol
Chem. 275:1887–1896. 2000.
|
|
29
|
Pallis M, Turzanski J, Higashi Y and
Russell N: P-glycoprotein in acute myeloid leukaemia: therapeutic
implications of its association with both a multidrug-resistant and
an apoptosis-resistant phenotype. Leuk Lymphoma. 43:1221–1228.
2002. View Article : Google Scholar
|
|
30
|
Ruefli AA, Tainton KM, Darcy PK, Smyth MJ
and Johnstone RW: P-glycoprotein inhibits caspase-8 activation but
not formation of the death inducing signal complex (disc) following
Fas ligation. Cell Death Differ. 9:1266–1272. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Turzanski J, Grundy M, Shang S, Russell N
and Pallis M: P-glycoprotein is implicated in the inhibition of
ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by
modulation of the glucosylceramide synthase pathway. Exp Hematol.
33:62–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schuurhuis GJ, Pinedo HM, Broxterman HJ,
van Kalken CK, Kuiper CM and Lankelma J: Differential sensitivity
of multi-drug-resistant and -sensitive cells to
resistance-modifying agents and the relation with reversal of
anthracycline resistance. Int J Cancer. 46:330–336. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ludwig JA, Szakacs G, Martin SE, et al:
Selective toxicity of NSC73306 in MDR1-positive cells as a new
strategy to circumvent multidrug resistance in cancer. Cancer Res.
66:4808–4815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hall MD, Handley MD and Gottesman MM: Is
resistance useless? Multidrug resistance and collateral
sensitivity. Trends Pharmacol Sci. 30:546–556. 2009. View Article : Google Scholar : PubMed/NCBI
|
